Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27863708 | 0.82 | TK1 (0.44) | TK1TSHRALDH1A1CTSKDUT | |
| SCHEMBL8588054 | 0.82 | TK1 (0.44) | TK1TSHRALDH1A1CTSKDUT | |
| SCHEMBL11800596 | 0.82 | TK1 (0.44) | TK1TSHRALDH1A1CTSKDUT | |
| SCHEMBL6667600 | 0.81 | TK1 (0.43) | TK1TSHRALDH1A1CTSKDUT | |
| SCHEMBL10565436 | 0.77 | TSHR (0.37) | TK1TSHRALDH1A1HTTCTSK | |
| SCHEMBL24587233 | 0.74 | TK1 (0.48) | TK1TSHRALDH1A1CTSKDUT | |
| SCHEMBL6516985 | 0.74 | TK1 (0.48) | TK1TSHRALDH1A1CTSKDUT | |
| SCHEMBL27859924 | 0.72 | CA1 (0.45) | TK1TSHRALDH1A1HTTCTSK | |
| SCHEMBL7136307 | 0.72 | LMNA (0.33) | — | |
| SCHEMBL2619910 | 0.71 | MEN1 (0.43) | TK1TSHRALDH1A1HTTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493498-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2016-11-15 | — | — | US | claimed |
| US-20150175643-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2015-06-25 | — | — | US | claimed |
| EP-2465542-B1 | Oligosaccharide-protein conjugates | GENZYME CORP (US) | 2015-01-21 | — | — | EP | claimed |
| US-8835614-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2014-09-16 | — | — | US | claimed |
| EP-2465542-A1 | Oligosaccharide-protein conjugates | Genzyme Corporation (US) | 2012-06-20 | — | — | EP | claimed |
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2011-12-08 | — | — | US | claimed |
| US-12252504-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2025-03-18 | — | — | US | disclosed |
| EP-4212541-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES AND THEIR INTERMEDIATES | Genzyme Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220242899-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-11279725-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2022-03-22 | — | — | US | disclosed |
| CN-112618724-A | Oligosaccharide-protein conjugates | 建新公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112220930-A | Oligosaccharide-protein conjugates | 建新公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20200216485-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2020-07-09 | — | — | US | disclosed |
| US-20150175643-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2015-06-25 | — | — | US | disclosed |
| EP-2465542-B1 | Oligosaccharide-protein conjugates | GENZYME CORP (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8835614-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2465542-A1 | Oligosaccharide-protein conjugates | Genzyme Corporation (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2011-12-08 | — | — | US | disclosed |
| EP-2376123-A2 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | Genzyme Corporation (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010075010-A2 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242899-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | TK1 1674/4885TSHR 2930/4885ALDH1A1 2313/4885 |
| US-20200216485-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | TK1 1674/4885TSHR 2930/4885ALDH1A1 2313/4885 |
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | TK1 1674/4885TSHR 2930/4885ALDH1A1 2313/4885 |
| US-20150175643-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | TK1 1674/4885TSHR 2930/4885ALDH1A1 2313/4885 |
| US-11279725-B2 | Oligosaccharide-protein conjugates | MAN2B1, GAA, GBA1 | TK1 1674/4885TSHR 2930/4885ALDH1A1 2313/4885 |
| US-12252504-B2 | Oligosaccharide-protein conjugates | MAN2B1, GAA, GBA1 | TK1 1674/4885TSHR 2930/4885ALDH1A1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.